Kava extract as well as preparation method and buccal product thereof

Abstract

The invention belongs to the technical field of buccal products, and relates to a kava extract, a preparation method thereof and a buccal product, and the kava extract comprises kava lactone. The kava extract provided by the invention contains active ingredients such as kavalactone and the like, and can act on the emotion center of the brain to exert the physiological effect, so that an eater of the buccal product can relax the mind and body, relieve pressure, relieve anxiety, correct depression and promote sleep; besides, the effect of the kava extract is similar to that of nicotine and nicotine salt, the kava extract is used for replacing nicotine and nicotine salt, the addiction phenomenon can be relieved, and meanwhile stimulation of nicotine and nicotine salt to oral mucosa and gastric mucosa can be relieved or avoided; besides, the kava extract has pepper flavor, so that consumers feel spicy flavor and taste of pepper in the process of using the buccal product, and unique flavor experience is brought to the consumers.

Description

Technical Field

[0001] The present application relates to the technical field of oral products, and in particular to a kava extract and a preparation method thereof, and an oral product. Background Art

[0002] Nicotine oral products generally use nicotine derivatives as direct raw materials. Nicotine oral products are prepared by mixing nicotine derivatives with other fillers and flavors. The human body absorbs nicotine through the oral mucosa. Existing nicotine oral products have a high nicotine content, which can easily cause addiction. At the same time, nicotine absorption through the mucosa is very irritating to the oral mucosa and gastric mucosa. Summary of the invention

[0003] The purpose of the embodiments of the present application is to provide a kava extract and a preparation method and an oral product thereof, so as to solve the problem that the nicotine oral products in the prior art have a high nicotine content, which can easily cause addiction, and at the same time, the absorption of nicotine through the mucosa has a great irritation to the oral mucosa and gastric mucosa.

[0004] In order to solve the above technical problems, an embodiment of the present application provides a kava extract for use in oral products, wherein the kava extract includes kavalactones.

[0005] Furthermore, in the kava extract, the mass percentage of kavalactones is 30% to 70%.

[0006] The present application also provides a method for preparing kava extract, comprising the following steps:

[0007] Obtaining Piper methysticum and crushing the Piper methysticum to obtain Piper methysticum powder;

[0008] Adding ethanol to the kava pepper powder for extraction and filtering to obtain an extract;

[0009] Concentrating the extract to obtain an extract;

[0010] adding a dispersant to the extract to obtain a kava extract;

[0011] The kava extract is dried to obtain the kava extract.

[0012] Furthermore, in the step of adding ethanol to the kava powder for extraction and filtering to obtain an extract, the extraction temperature is 65° C. to 85° C., and / or the ethanol concentration is 90%, and / or the mass ratio of the kava powder to the ethanol is 1:(10-15), and / or the extraction time is 60 min to 120 min.

[0013] The present application also provides an oral preparation, which includes a kava extract. The kava extract is the kava extract described above, or the kava extract prepared by the method described above.

[0014] Furthermore, in the oral product, the mass percentage of the kava extract is 3% to 20%.

[0015] Furthermore, the oral preparation also includes flavor ingredients, fillers and humectants;

[0016] In the oral product, the mass percentage of the flavor component is 0% to 60%, the mass percentage of the filler is 0% to 60%, and the mass percentage of the humectant is 0% to 3%;

[0017] And / or, in the oral product, the mass percentage of the total mass of the flavor component, the filler and the humectant is 0% to 60%.

[0018] Furthermore, the oral product further comprises water, sodium chloride, an acid-base regulator, an antioxidant and a preservative, the filler comprises cellulose, and the flavor component comprises a flavoring agent and a cooling agent;

[0019] Among them, in the oral product, the mass percentage of the cellulose is 40% to 60%, the mass percentage of the water is 10% to 30%; the mass percentage of the sodium chloride is 3% to 5%, the mass percentage of the acid-base regulator is 1% to 5%, the mass percentage of the flavoring agent is 1% to 15%, the mass percentage of the humectant is 1% to 5%, the mass percentage of the cooling agent is 1% to 4%, the mass percentage of the antioxidant is 1% to 5%, and the mass percentage of the preservative is 0.5% to 1%.

[0020] Furthermore, the oral preparation also includes L-tryptophan.

[0021] Furthermore, in the oral product, the mass percentage of L-tryptophan is 1% to 5%.

[0022] Compared with the prior art, the embodiments of the present application have the following beneficial effects:

[0023] The kava extract provided by the present invention is applied to oral products, wherein the kava extract includes kava lactones. On the one hand, active ingredients such as kava lactones in the kava extract can act on the emotional center of the brain to exert their physiological effects, so that the consumer of the oral product can relax the mind and body, reduce stress, relieve anxiety, correct depression, and promote sleep. The efficacy of the kava extract is similar to that of nicotine and nicotine salts. Replacing part or all of the nicotine and nicotine salt components with the kava extract can reduce addiction, and at the same time can slow down or avoid the stimulation of nicotine and nicotine salts to the oral mucosa and gastric mucosa; on the other hand, the kava extract has a peppery taste, so that consumers can feel the peppery fragrance and taste when using the oral product, bringing consumers a unique flavor experience. DETAILED DESCRIPTION

[0024] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0025] It should be understood that when used in this specification and the appended claims, the terms "include" and "comprises" indicate the presence of described features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or combinations thereof.

[0026] It should also be understood that the terms used in this specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. As used in the specification of the present invention and the appended claims, unless the context clearly indicates otherwise, the singular forms "a", "an" and "the" are intended to include plural forms.

[0027] It should be further understood that the term "and / or" used in the present description and the appended claims refers to any and all possible combinations of one or more of the associated listed items, and includes these combinations.

[0028] In order to more fully understand the technical content of the present invention, the technical solution of the present invention is further introduced and illustrated in conjunction with specific embodiments below.

[0029] In order to solve the above technical problems, an embodiment of the present application provides a kava extract for use in oral products, wherein the kava extract includes kavalactones.

[0030] In this embodiment, the active ingredients such as kavalactone in the kava extract can act on the emotional center of the brain to exert their physiological effects, so that the consumer of the oral product can relax the mind and body, reduce stress, relieve anxiety, correct depression, and promote sleep. The efficacy of kava extract is similar to that of nicotine and nicotine salts. Replacing part or all of the nicotine and nicotine salt components with kava extract can reduce addiction, and at the same time can slow down or avoid the stimulation of nicotine and nicotine salts to the oral mucosa and gastric mucosa, while reducing the harm caused by nicotine and nicotine salts. It can also achieve a health care effect; on the other hand, kava extract has a peppery taste, which allows consumers to feel the peppery aroma and taste when using the oral product, giving consumers a unique flavor experience.

[0031] Furthermore, in the kava extract, the mass percentage of kavalactones is 30% to 70%.

[0032] Specifically, the mass percentage of kavalactone is any one of 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, etc., or a range between any two of them.

[0033] In another embodiment of the present application, a method for preparing kava extract is provided, comprising the following steps:

[0034] S1: obtaining Piper mesenteriae kava, crushing the Piper mesenteriae kava, and passing the mixture through a 40-mesh sieve to obtain Piper mesenteriae kava powder;

[0035] S2: adding ethanol to the kava pepper powder for extraction and filtering to obtain an extract;

[0036] S3: Concentrating the extract to obtain an extract;

[0037] S4: adding a dispersant to the extract to obtain a kava extract;

[0038] S5: Drying the kava extract to obtain the kava extract.

[0039] In step S1, the source of kava powder can be one or more of the rhizomes, leaves, fruits, etc. of kava. Preferably, the kava powder is derived from the rhizomes of kava, and the content of kavalactone in the rhizomes of kava is relatively high.

[0040] Further, in step S2, the ethanol extraction temperature is 65°C to 85°C, and / or the ethanol concentration is 90%, and / or the extraction time is 60min to 120min, and / or the mass ratio of the kava pepper powder to the ethanol liquid is 1:(10-15), specifically, the mass ratio of the kava pepper powder to the ethanol liquid is 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, etc., or in the range of any one or any two thereof.

[0041] Furthermore, in step S3, the method for concentrating the extract is not limited, and the extract can be concentrated by reduced pressure concentration, vacuum concentration, low temperature concentration and other means.

[0042] Furthermore, in step S4, the type of the dispersant is not limited, and the dispersant can be selected from one or more of water, methanol, ethanol, propylene glycol, chloroform, ether, benzene, and petroleum ether.

[0043] The embodiment of the present application also provides an oral product, including kava extract, wherein the kava extract adopts the kava extract as described above, or the kava extract prepared by the method as described above. The active ingredients such as kavalactone in the kava extract can act on the emotional center of the brain to exert their physiological effects, so that the consumer of the oral product can relax the mind and body, reduce stress, relieve anxiety, correct depression, and promote sleep. The efficacy of kava extract is similar to that of nicotine and nicotine salts. Replacing part or all of the nicotine and nicotine salt components with kava extract can reduce addiction, and at the same time can slow down or avoid the stimulation of nicotine and nicotine salts on the oral mucosa and gastric mucosa, while reducing the harm caused by nicotine and nicotine salts, it can also achieve the effect of health care; on the other hand, the kava extract has a peppery taste, so that consumers can feel the peppery fragrance and taste in the process of using the oral product, bringing consumers a unique flavor experience.

[0044] In one embodiment, in the oral preparation, the mass percentage of the kava extract is 3% to 20%. Specifically, the mass percentage of the kava extract is any one of 3%, 5%, 10%, 13%, 15%, 18%, 20%, etc. or any two thereof.

[0045] Furthermore, the oral preparation also includes flavor ingredients, fillers and humectants; in the oral preparation, the mass percentage of the flavor ingredients is 0% to 60%, the mass percentage of the fillers is 0% to 60%, and the mass percentage of the humectants is 0% to 3%. Specifically, the mass percentage of the flavor ingredients is any one of 0%, 10%, 20%, 30%, 40%, 50%, 60%, etc., or any two of them; the mass percentage of the fillers is any one of 0%, 10%, 20%, 30%, 40%, 50%, 60%, etc., or any two of them; the mass percentage of the humectants is any one of 0%, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, etc., or any two of them.

[0046] In another embodiment, the total mass percentage of the flavor component, the filler and the humectant in the oral product is 0% to 60%. Specifically, the total mass percentage of the flavor component, the filler and the humectant in the oral product is any one of 0%, 10%, 20%, 30%, 40%, 50%, 60%, etc., or any two of them.

[0047] Furthermore, the oral preparation also includes water, sodium chloride, an acid-base regulator, an antioxidant and a preservative, the filler includes cellulose, and the flavor ingredients include flavoring agents and cooling agents; wherein, in the oral preparation, the mass percentage of the cellulose is 40% to 60%, the mass percentage of the water is 10% to 30%; the mass percentage of the sodium chloride is 3% to 5%, the mass percentage of the acid-base regulator is 1% to 5%, the mass percentage of the flavoring agent is 1% to 15%, the mass percentage of the humectant is 1% to 5%, the mass percentage of the cooling agent is 1% to 4%, the mass percentage of the antioxidant is 1% to 5%, and the mass percentage of the preservative is 0.5% to 1%.

[0048] Furthermore, the cellulose is selected from one or more of natural fibers, microcrystalline cellulose, and cellulose derivatives.

[0049] Furthermore, the acid-base regulator is selected from one or both of sodium bicarbonate and sodium carbonate.

[0050] Furthermore, the flavoring agent is selected from one or more of monosaccharides, disaccharides, trisaccharides, polysaccharides, polyols, and sweeteners.

[0051] Furthermore, the humectant is selected from one or both of propylene glycol and glycerol.

[0052] Furthermore, the cooling agent is selected from one or more of WS-23, menthol, and WS-5.

[0053] Furthermore, the antioxidant is selected from one or more of vitamin A, vitamin C, and vitamin E.

[0054] Furthermore, the preservative is selected from one or more of benzoic acid, sodium benzoate, sorbic acid, potassium sorbate, and calcium propionate.

[0055] In one embodiment, the oral preparation further includes L-tryptophan. In this embodiment, L-tryptophan is an important precursor substance for the biosynthesis of auxin in plants, and is also a precursor of the important neurotransmitter 5-hydroxytryptamine in the human body. L-tryptophan can regulate mental rhythm and improve sleep. L-tryptophan has a strong synergistic effect on the effect of kava extract, and can also exert the unique health care, immunity and antioxidant functions of L-tryptophan; the oral preparation includes kava extract and L-tryptophan at the same time, which has a synergistic effect on regulating stress, depression and insomnia, and calming the nerves and helping sleep.

[0056] In one embodiment, in the oral preparation, the mass percentage of L-tryptophan is 1% to 5%. Specifically, the mass percentage of L-tryptophan is any one of 1%, 2%, 3%, 4%, 5%, etc., or a range between any two.

[0057] The above scheme is further described below in conjunction with specific examples. If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional reagent products that can be purchased commercially.

[0058] L-Tryptophan was purchased from Jiangsu Duoyang Bioengineering Technology Co., Ltd.

[0059] Example 1

[0060] The present application provides an oral product, and the preparation method is as follows:

[0061] Step 1: providing the following components in parts by weight: 3% kava extract, 58.5% microcrystalline cellulose, 20% water, 3% sodium chloride, 4% vitamin C, 2% WS-23 and 2% sodium bicarbonate, and mixing the above components evenly, and refrigerating for 12 hours to obtain a preform;

[0062] Step 2: Spray the following components by weight on the preformed product: 2% fructose syrup, 4% glucose, 1% acesulfame potassium and 0.5% potassium sorbate, pass through a 20-mesh sieve, seal and refrigerate for 24 hours, and sterilize with ultraviolet light for 3 hours to obtain an oral preparation.

[0063] Example 2

[0064] The difference from Example 1 is that:

[0065] In step 2, the mass fraction of kava extract is 5%, and the mass fraction of microcrystalline cellulose is 56.5%.

[0066] Example 3

[0067] The difference from Example 1 is that:

[0068] In step 2, the mass fraction of kava extract is 8%, and the mass fraction of microcrystalline cellulose is 53.5%.

[0069] Example 4

[0070] The difference from Example 1 is that:

[0071] In step 2, the mass fraction of kava extract is 10%, and the mass fraction of microcrystalline cellulose is 51.5%.

[0072] Example 5

[0073] The difference from Example 1 is that:

[0074] In step 2, the mass fraction of kava extract is 15%, and the mass fraction of microcrystalline cellulose is 46.5%.

[0075] Example 6

[0076] The difference from Example 1 is that:

[0077] In step 2, the mass fraction of kava extract is 20%, and the mass fraction of microcrystalline cellulose is 41.5%.

[0078] Example 7

[0079] The present application provides an oral product, and the preparation method is as follows:

[0080] Step 1: providing the following components in parts by weight: 3% kava extract, 57.5% microcrystalline cellulose, 1% L-tryptophan, 20% water, 3% sodium chloride, 4% vitamin C, 2% WS-23 and 2% sodium bicarbonate, and mixing the above components evenly, and refrigerating for 12 hours to obtain a preform;

[0081] Step 2: Spray the following components by weight on the preformed product: 2% fructose syrup, 4% glucose, 1% acesulfame potassium and 0.5% potassium sorbate, pass through a 20-mesh sieve, seal and refrigerate for 24 hours, and sterilize with ultraviolet light for 3 hours to obtain an oral preparation.

[0082] Example 8

[0083] The difference from Example 7 is that:

[0084] In step 2, the mass fraction of kava extract is 5%, and the mass fraction of microcrystalline cellulose is 55.5%.

[0085] Example 9

[0086] The difference from Example 7 is that:

[0087] In step 2, the mass fraction of kava extract is 8%, the mass fraction of microcrystalline cellulose is 50.5%, and the mass fraction of L-tryptophan is 3%.

[0088] Example 10

[0089] The difference from Example 7 is that:

[0090] In step 2, the mass fraction of kava extract is 10%, the mass fraction of microcrystalline cellulose is 48.5%, and the mass fraction of L-tryptophan is 3%.

[0091] Embodiment 11

[0092] The difference from Example 7 is that:

[0093] In step 2, the mass fraction of kava extract is 15%, the mass fraction of microcrystalline cellulose is 41.5%, and the mass fraction of L-tryptophan is 5%.

[0094] Example 12

[0095] The difference from Example 7 is that:

[0096] In step 2, the mass fraction of kava extract is 20%, the mass fraction of microcrystalline cellulose is 36.5%, and the mass fraction of L-tryptophan is 5%.

[0097] Comparative Example 1

[0098] The comparative example of the present application provides an oral product, and the preparation method is as follows:

[0099] Step 1: providing the following components in parts by weight: 5% nicotine-tartrate, 56.5% microcrystalline cellulose, 20% water, 3% sodium chloride, 4% vitamin C, 2% WS-23 and 2% sodium bicarbonate, and mixing the above components evenly, and refrigerating for 12 hours to obtain a preform;

[0100] Step 2: Spray the following components by weight on the preformed product: 2% fructose syrup, 4% glucose, 1% acesulfame potassium and 0.5% potassium sorbate, pass through a 20-mesh sieve, seal and refrigerate for 24 hours, and sterilize with ultraviolet light for 3 hours to obtain an oral preparation.

[0101] Comparative Example 2

[0102] The comparative example of the present application provides an oral product, and the preparation method is as follows:

[0103] Step 1: providing the following components by weight: 61.5% microcrystalline cellulose, 20% water, 3% sodium chloride, 4% vitamin C, 2% WS-23 and 2% sodium bicarbonate, and mixing the above components evenly, and refrigerating for 12 hours to obtain a preform;

[0104] Step 2: Spray the following components by weight on the preformed product: 2% fructose syrup, 4% glucose, 1% acesulfame potassium and 0.5% potassium sorbate, pass through a 20-mesh sieve, seal and refrigerate for 24 hours, and sterilize with ultraviolet light for 3 hours to obtain an oral preparation.

[0105] Sensory test

[0106] 20 professionally trained tasters (male: female = 1:1, average age 25-35 years old) were selected to form a scoring team. The tasters conducted sensory evaluation on Examples 1-12 and Comparative Examples 1-2 according to the items in the sensory scoring item table in Table 1, and took the average value. Team members must not smoke or drink alcohol within 2 hours before the evaluation, and must not eat foods with strong odors. Each time, take a piece of oral product and place it on the gums under the upper lip to feel the fragrance, taste, and strength of different samples and score them. The stopwatch counts the duration of the head feeling. Taste each sample for at least 30 minutes, then spit it out, rinse your mouth several times until there is no residual taste in the mouth, and measure the next group of samples in the same way after 10 minutes. After the test is completed, the sensory test results in Table 2 are obtained.

[0107] Table 1 Sensory scoring items

[0108]

[0109]

[0110] Table 2 Sensory test results

[0111]

[0112]

[0113] According to the evaluation results in Table 2, combined with Examples 1 to 12 and Comparative Examples 1 to 2, it is shown that the kava extract of the present invention not only makes the product have better peppery spiciness and taste, bringing consumers a unique flavor experience, but also can reduce irritation to the oral cavity and improve the comfort of taking oral products; in addition, the kava extract can provide consumers with the same heady feeling and stimulation as nicotine and nicotine salts. Replacing part or all of the nicotine and nicotine salt components with kava extract can reduce addiction, and at the same time can slow down or avoid the stimulation of nicotine and nicotine salts to the oral mucosa and gastric mucosa, while reducing the harm caused by nicotine and nicotine salts, it can also achieve a health care effect.

[0114] References throughout the specification to "some embodiments", "partial embodiments", "one embodiment", "another example", "example", "specific example" or "partial example" mean that at least one embodiment or example in the present application includes the specific features, structures, materials or characteristics described in the embodiment or example. Therefore, descriptions appearing in various places throughout the specification, such as: "in some embodiments", "in an embodiment", "in one embodiment", "in another example", "in an example", "in a specific example" or "example", do not necessarily refer to the same embodiment or example in the present application. In addition, the specific features, structures, materials or characteristics herein may be combined in one or more embodiments or examples in any suitable manner.

[0115] Although illustrative embodiments have been demonstrated and described, those skilled in the art should understand that the above embodiments should not be construed as limitations on the present application, and that changes, substitutions and modifications may be made to the embodiments without departing from the spirit, principles and scope of the present application.

Claims

1. A kava extract, applied to oral products, characterized in that: The kava extract includes kavalactones.

2. The kava extract according to claim 1, characterized in that In the kava extract, the mass percentage of kavalactone is 30% to 70%.

3. A method for preparing kava extract, characterized in that: The steps include: Obtaining Piper methysticum and crushing the Piper methysticum to obtain Piper methysticum powder; Adding ethanol to the kava pepper powder for extraction and filtering to obtain an extract; Concentrating the extract to obtain an extract; adding a dispersant to the extract to obtain a kava extract; The kava extract is dried to obtain the kava extract.

4. The preparation method according to claim 3, characterized in that: In the step of adding ethanol to the kava powder for extraction and filtering to obtain an extract, the extraction temperature is 65° C. to 85° C., and / or the ethanol concentration is 90%, and / or the mass ratio of the kava powder to the ethanol is 1:(10-15), and / or the extraction time is 60 min to 120 min.

5. An oral product, characterized in that: The oral preparation comprises kava extract, and the kava extract is the kava extract described in claim 1 or 2, or the kava extract prepared by the method described in claim 3 or 4.

6. The oral product according to claim 5, characterized in that In the oral product, the mass percentage of the kava extract is 3% to 20%.

7. The oral product according to claim 6, characterized in that The oral preparation further comprises a flavor component, a filler and a humectant; In the oral product, the mass percentage of the flavor component is 0% to 60%, the mass percentage of the filler is 0% to 60%, and the mass percentage of the humectant is 0% to 3%; And / or, in the oral product, the mass percentage of the total mass of the flavor component, the filler and the humectant is 0% to 60%.

8. The oral product according to claim 7, characterized in that The oral product further comprises water, sodium chloride, an acid-base regulator, an antioxidant and a preservative, the filler comprises cellulose, and the flavor component comprises a flavoring agent and a cooling agent; Among them, in the oral product, the mass percentage of the cellulose is 40% to 60%, the mass percentage of the water is 10% to 30%; the mass percentage of the sodium chloride is 3% to 5%, the mass percentage of the acid-base regulator is 1% to 5%, the mass percentage of the flavoring agent is 1% to 15%, the mass percentage of the humectant is 1% to 5%, the mass percentage of the cooling agent is 1% to 4%, the mass percentage of the antioxidant is 1% to 5%, and the mass percentage of the preservative is 0.5% to 1%.

9. The oral product according to any one of claims 5 to 8, characterized in that: The oral preparation also includes L-tryptophan.

10. The oral product according to claim 9, characterized in that In the oral product, the mass percentage of L-tryptophan is 1% to 5%.

Images